The US company’s repertoire of T cell receptor antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science.

In April 2021, Repertoire completed a $189 million Series B financing to support the broad application of its DECODE platform to define and understand the complete repertoire of T cell receptor-antigen pairs that drive cellular immunity. The insight gleaned from this information will enable a new era of new immune medicines designed to exploit these critical interactions.

Founded by Flagship Pioneering, Repertoire has raised more than $350 million in the aggregate to date.